Status:
COMPLETED
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers
Lead Sponsor:
Xuanwu Hospital, Beijing
Collaborating Sponsors:
Michael J. Fox Foundation for Parkinson's Research
Conditions:
Parkinson Disease
Eligibility:
All Genders
55+ years
Brief Summary
The goals of this study are 1. To compare the functional effects of the LRRK2 G2385R variant among carriers with and without Parkinson's disease (PD) and non-carriers with and without PD 2. To invest...
Detailed Description
Pharmaceutical companies with LRRK2 kinase inhibitor programs are close to Phase 1 clinical testing. Phase II proof-of-concept clinical trials will need to be conducted in LRRK2 manifesting mutation c...
Eligibility Criteria
Inclusion
- PD patients:
- A diagnosis of Parkinson's disease according to the 2015 MDS PD diagnostic criteria.
- Willingness to take genetic testing.
- Unaffected subjects:
- Individuals aged 55 years or older without a diagnosis of PD.
- Willingness to take genetic testing.
Exclusion
- □ Clinically significant neurological disorders.
Key Trial Info
Start Date :
May 22 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 25 2020
Estimated Enrollment :
211 Patients enrolled
Trial Details
Trial ID
NCT04349865
Start Date
May 22 2018
End Date
December 25 2020
Last Update
February 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu Hospital of Capital Medical University
Beijing, China